The U.S. Food and Drug Administration (FDA) has just approved Zingo(TM)(lidocaine hydrochloride monohydrate) powder intradermal injection system,which provides rapid, topical, local analgesia to reduce the pain associatedwith venous access procedures, such as IV insertions or blood draws, inchildren ages three to 18.
For a child, a trip to the hospital can be a frightening experience, andthe stress associated with undergoing a venous access procedure such as ablood draw or IV insertion often escalates their anxiety. Each year inhospitals in the United States, approximately 18 million venous accessprocedures are performed on children.
Pain associated with blood draws and IV insertions is one of the mostcommon anxiety-provoking hospital procedures in children and often sets thetone for the entire hospital visit. In fact, a study published in the journalPediatric Nursing shows that IV insertions and blood draws are the mostfrequently reported painful events in hospitalized children. For moreinformation visit, www.anesiva.com.
Preview and access this video on Pathfire DMG: Slug # 29227
Search within the PR Newswire or MultiVu section by story ID # 29227 orby headline
For technical assistance call Pathfire Customer Care at 1-888-345-0489 ore-mail email@example.com
ADDITIONAL RESOURCES: Video, contact information and more available at:http://www.prnewswire.com/broadcast/29227/consumer.html
VIDEO PROVIDED BY: Anesiva, Inc.
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313 EXT. 3SATELLITE FEEDS: Friday, August 17th, 2007 Friday, August 17th, 2007 10:30 AM - 10:45 AM ET 1:45 PM - 2:00 PM ET Galaxy 26 Galaxy 26 C-Band C-Band Transponder 5 Transponder 5 Downlink Freq. 3800 Vertical Downlink Freq. 3800 Vertical Friday, August 17th, 2007 6:30 PM - 6:45 PM ET Galaxy 26 C-Band Transponder 15 Downlink Freq. 4000 Vertical
SOURCE Anesiva, Inc.